Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/10/2023 | $22.00 | Buy | Guggenheim |
| 11/8/2021 | $32.00 → $34.00 | Outperform | Oppenheimer |
On track to report interim data in six-month evaluable patients in ADVANCED-2 trial of TARA-002 in NMIBC in 4Q 2024Expect to report interim 12-month data in ADVANCED-2 trial of TARA-002 in NMIBC in mid-2025In pediatric LMs patients, TARA-002 demonstrated encouraging results and was generally well-tolerated in the first cohort of Phase 2 STARBORN-1 trial; initial results from next cohort expected in 1H 2025Received Fast Track designation from the U.S. FDA for IV Choline Chloride; expect to dose first patient in THRIVE-3 registrational trial in 1Q 2025 NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage company developing transformative the
Remain on track to initiate registrational THRIVE-3 trial in 1Q' 2025 NEW YORK, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Intravenous (IV) Choline Chloride, the Company's investigational IV phospholipid substrate replacement therapy, as a source of choline for adult and adolescent patients on parenteral support (PS) for whom oral or enteral nutrition is not possible, insufficient, or contraindicated. In the U.S. alone, there are approximately 4
TARA-002 demonstrated compelling efficacy and was generally well-tolerated Enrollment in additional cohorts underway with initial results expected in 1H'25 NEW YORK, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced completion of the first cohort of the Phase 2 STARBORN-1 trial evaluating TARA-002, an investigational cell-based immunopotentiator, for the treatment of pediatric patients with lymphatic malformations (LMs). Enrollment is now underway in additional cohorts. "The initial data is compelling and reflective of the significa
4 - Protara Therapeutics, Inc. (0001359931) (Issuer)
4 - Protara Therapeutics, Inc. (0001359931) (Issuer)
4 - Protara Therapeutics, Inc. (0001359931) (Issuer)
Guggenheim resumed coverage of Protara Therapeutics with a rating of Buy and set a new price target of $22.00
Oppenheimer reiterated coverage of Protara Therapeutics with a rating of Outperform and set a new price target of $34.00 from $32.00 previously
HC Wainwright & Co. initiated coverage of Protara Therapeutics with a rating of Buy and set a new price target of $40.00
10-Q - Protara Therapeutics, Inc. (0001359931) (Filer)
S-8 - Protara Therapeutics, Inc. (0001359931) (Filer)
10-Q - Protara Therapeutics, Inc. (0001359931) (Filer)
https://blog.tipranks.com/these-2-strong-buy-penny-stocks-could-surge-over-400-says-oppenheimer/
HC Wainwright & Co. analyst Andrew Fein reiterates Protara Therapeutics (NASDAQ:TARA) with a Buy and maintains $23 price target.
Protara Therapeutics (NASDAQ:TARA) reported quarterly losses of $(0.97) per share which missed the analyst consensus estimate of $(0.95) by 2.11 percent. This is a 21.25 percent decrease over losses of $(0.80) per share from the same period last year.
SC 13G - Protara Therapeutics, Inc. (0001359931) (Subject)
SC 13G - Protara Therapeutics, Inc. (0001359931) (Subject)
SC 13G/A - Protara Therapeutics, Inc. (0001359931) (Subject)
- Phase 1 Study of TARA-002 in Patients with Non-Muscle Invasive Bladder Cancer Under Way - - Strong Cash Position of $130.7M as of December 31, 2021 Expected to Fund Operations into Mid-2024 - NEW YORK, March 09, 2022 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced financial results for the fourth quarter and year ended December 31, 2021 and provided a business update. "Following a productive 2021, we are well poised to advance our pipeline in 2022, in particular, we are excited to have commenced our Phase 1 study of TARA-002 in non-muscle invasive b
NEW YORK, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the appointment of Jathin Bandari, M.D., as Chief Medical Officer. Dr. Bandari is a practicing urologic oncologist, recently serving at the University of Rochester where he specialized in both minimally invasive urologic oncology and advanced open pelvic retroperitoneal cancer surgery, and where he maintains a faculty appointment. Dr. Bandari joined Protara in April 2020 as Vice President, Head of Clinical Development, and most recently was Interim Chief Medical Officer. "We are thr
- Successfully Completed IND-Enabling Studies for TARA-002 in Patients with NMIBC; On Track to Initiate Phase 1 Trial by Year-End - - TARA-002 GMP Scale up and Comparability Ongoing and Expected to be Completed by Year-End - - Company Plans to Engage with FDA to Determine Clinical Trial Design for TARA-002 in Lymphatic Malformations - - Strong Cash, Cash Equivalents, and Investments Position of $145M as of June 30, 2021 - NEW YORK, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced financial results for the se